Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 54.21$. Average daily volumn in 3 months 1.73M. Market cap 134.02B

Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD
Lastest price : 51.03$. Total volume : 995.43k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Sanofi (SNY)
Last Price

Previous Close50.45
Day Range50.40-51.05
Bid50.93 x 900
Ask50.93 x 1.2k
Average Volume1.73M
Market Cap134.02B
52 Week Range36.91-57.82
Trailing P/E14.30
Foward P/E5.80
Dividend (Yield %)3.77%
Ex-Dividend Date2023-05-30

Financial Details

According to Sanofi's financial reports the company's revenue in 2022 were 45.39B an increase( +15.38%) over the years 2021 revenue that were of 39.17B. In 2022 the company's total earnings were 8.37B while total earnings in 2021 were 6.22B( +33.33%).

Loading ...



Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers po... liomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Market Cap:
Total Assets:
Total Cash:

News about "Sanofi"


Sanofi announces positive data for frexalimab product to treat multiple sclerosis

Source from : Reuters - 22 hours ago

French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple ...See details»

Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal

Source from : MSN - 10 hours ago

Sanofi SNY announced positive data from a phase II study, which showed that its novel investigational anti-CD40L antibody, frexalimab, significantly reduced disease activity in patients with relapsing ...See details»

J.P. Morgan Sticks to Their Buy Rating for Sanofi (SNYNF)

Source from : Business Insider - 17 hours ago

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Sanofi (SNYNF โ€“ Research Report), with a price ...See details»


Sanofi announces positive data for frexalimab in relapsing MS

Source from : PharmaTimes - 15 hours ago

The neurological disease affects approximately 2.8 million people worldwide Sanofi has reported positive new data from a mid-stage study of its investigational anti-CD40L antibody in patients with ...See details»

Sanofi: Frexalimab Phase 2 Trial Meets Primary Goal In Relapsing Multiple Sclerosis

Source from : Business Insider - 21 hours ago

French drug major Sanofi S.A. (SNYNF, SNY) announced Wednesday positive Phase 2 data of novel investigational anti-CD40L antibody ...See details»

Sanofi's frexalimab shows promise in relapsing forms of MS

Source from : PMLiVE - 14 hours ago

Results from the phase 2 study, being presented at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab significantly reduced disease activity in patients with ...See details»


Sanofi CEO: โ€˜Europeโ€™s lead in life sciences R&D is erodingโ€“but co-localized hubs could allow it to keep upโ€™

Source from : Fortune on MSN - 14 days ago

In France, a recent public-private partnership presents a model for Europe to stay competitive with the U.S. and China in the life sciences. The country has recently endorsed the creation of the Paris ...See details»

Sanofi: smoker's lung drug benefit was swift and sustained in trial

Source from : Yahoo News - 9 days ago

(Reuters) - The benefits of Sanofi and Regeneron's anti-inflammatory drug Dupixent set in quickly during a trial to treat "smoker's lung" and lasted for the duration of the 1-year study, French ...See details»

Sanofi (SNY) Stock Moves -0.45%: What You Should Know

Source from : Nasdaq - 1 month ago

Sanofi (SNY) closed at $55.47 in the latest trading session, marking a -0.45% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.6%. Meanwhile, the Dow lost 0.33% ...See details»

Sanofi completes acquisition of Provention Bio, Inc.

Source from : PharmiWeb - 1 month ago

โ€œWe are excited to finalize our acquisition of Provention Bio, Inc. This strategic fit for Sanofi lies at the intersection of our growth in immune-mediated diseases and disease-modifying therapies in ...See details»

Sanofi stock rises on licensing deal with Maze for potential Pompe disease drug

Source from : Seeking Alpha - 1 month ago

Sanofi (NASDAQ:SNY) signed a licensing agreement with Maze Therapeutics for a glycogen synthase 1 (GYS1) program, including MZE001. Maze is developing MZE001 to treat Pompe disease and for other ...See details»

Eli Lilly, Sanofi to cap insulin prices at $35 per month for uninsured New Yorkers

Source from : Seeking Alpha - 29 days ago

New York Attorney General Letitia James announced Tuesday that Eli Lilly (NYSE:LLY) and Sanofi (NASDAQ:SNY) agreed to cap the price of their insulin products at $35 per month for uninsured ...See details»

Sanofi signs agreement worth up to $750m for Mazeโ€™s Pompe disease drug

Source from : PMLiVE - 28 days ago

Sanofi has signed an exclusive worldwide licensing agreement with Maze Therapeutics for its glycogen synthase 1 (GYS1) programme, including a lead candidate for Pompe disease and other glycogen ...See details»

Sanofi, Flatiron to Collaborate on Clinical Trial Data Acquisition at Point of Care

Source from : The American Journal of Managed Care - 29 days ago

Pharmaceutical giant Sanofi and health care technology company Flatiron Health, known for its innovative oncology products, on Monday announced a partnership to develop standards for pulling data ...See details»